Evidence map›Paper›PMID 35145343›Full record

ReviewSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2022

Localizing pharmaceuticals manufacturing and its impact on drug security in Saudi Arabia.

Essam A Tawfik, Abdulkader F Tawfik, Areej M Alajmi, Moutaz Y Badr, Ahmed Al-Jedai, Nada H Almozain, Haitham A Bukhary, Abdulrahman A Halwani, Saeed A Al Awadh, Aws Alshamsan and 2 more

Abstract readReview
In one paragraph

Review in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Patient satisfaction with Saudi community pharmacy services (Wasfaty System).Journal of Taibah University Medical Sciences · 2024
    Article
  7. Trend of pharmaceuticals 3D printing in the Middle East and North Africa (MENA) region: An overview, regulatory perspective and future outlook.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  8. Article
  9. Review
  10. Article
  11. Current status and vision of local pharmaceutical industries in Saudi Arabia: The focus on nanomedicines.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  12. Article
  13. Article
  14. Estimating the potential economic impact of the Wasfaty program on costs of antidiabetic treatment: An initiative for the digital transformation of health.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  15. Current and future prospective of pharmaceutical manufacturing in Saudi Arabia.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Essam A TawfikNational Center of Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia.
Abdulkader F TawfikDrug Dimension Company, Riyadh, Saudi Arabia.
Areej M AlajmiNational Center of Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia.
Moutaz Y BadrDepartment of Pharmaceutics, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Ahmed Al-JedaiTherapeutic Affairs, Ministry of Health, Riyadh, Saudi Arabia.
Nada H AlmozainInpatient Department, Pharmaceutical Services Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Haitham A BukharyDepartment of Pharmaceutics, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Abdulrahman A HalwaniPharmaceutics Department, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Saeed A Al AwadhSaudi Food and Drug Authority, Drug Sector, Riyadh, Saudi Arabia.
Aws AlshamsanNanobiotechnology Unit, Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Salim BabhairFive Dimensions for Consultation Company, Riyadh, Saudi Arabia.
Abdulaziz M AlmalikNational Center of Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Local production of pharmaceuticals plays a vital role in maintaining resilience of national healthcare systems, especially when it comes to facilitating access to needed medicines and decreasing exposure to imports and international supply chains. Pharma is a research-intensive industry and the systemic lack of governance and support to R&D activities in this sector, among other host of related issues such as unsupportive regulatory regimes and human resources capacity limitations, is one of the major impediments to the diversifying of locally produced pharmaceuticals portfolio. In this review, an overview of the current pharmaceutical production system in Saudi Arabia, its major challenges, and proposed remedies to address them will be highlighted.

Indexed as

Pharmaceutical innovationPharmaceutical marketPharmaceutical production systemPharmaceuticals manufacturing in Saudi ArabiaResearch and development (R&D)

Identifiers

PMID35145343
PMCPMC8802089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.